Coronary Sinus Reducer Improves Angina, Quality of Life, and Coronary Flow Reserve in Microvascular Dysfunction
- PMID: 39520443
- DOI: 10.1016/j.jcin.2024.09.018
Coronary Sinus Reducer Improves Angina, Quality of Life, and Coronary Flow Reserve in Microvascular Dysfunction
Abstract
Background: Coronary microvascular dysfunction (CMD) is a common cause of angina with no obstructive coronary artery disease (ANOCA), and effective treatment options are limited.
Objectives: This study aims to assess the safety and efficacy of the coronary sinus (CS) Reducer (Neovasc, Inc/Shockwave Medical) for treatment of angina in patients with CMD.
Methods: This Phase II trial enrolled 30 patients with ANOCA, invasively diagnosed CMD, and Canadian Cardiovascular Society (CCS) class 3 to 4 angina despite medical therapy. CMD was defined by coronary flow reserve (CFR) ≤2.5 and/or ≤50% increase in coronary blood flow (CBF) in response to intracoronary infusion of acetylcholine. Invasive coronary microvascular function testing was performed before and at 120 days postimplantation. The primary endpoint was change in microvascular function at 120 days. Secondary endpoints were changes in CCS angina class and Seattle Angina Questionnaire (SAQ) scores.
Results: Mean age was 54.8 ± 11.0 years; 67% (20/30) were women. In patients with low baseline CFR (endothelium-independent CMD), CFR increased significantly from 2.1 (1.95-2.30) to 2.7 (2.45-2.95) (n = 19; P = 0.0011). Patients with abnormal CBF response to acetylcholine at baseline (endothelium-dependent CMD) had an increase in CBF response to acetylcholine: -11.0% (-20.15% to 5.85%) to 11.5% (-4.82% to 39.29%) (n = 11; P = 0.042). There was a significant improvement in CCS angina class from 4.0 (3.25-4.0) to 2.0 (2.0-3.0) (P < 0.001) and increase in each domain of the SAQ questionnaire (P < 0.006 for all).
Conclusions: This study demonstrates that the CS Reducer is associated with significant improvement in angina, quality of life, and coronary microvascular function in patients with CMD and may emerge as a novel therapy for patients with ANOCA.
Keywords: ANOCA; angina with no obstructive coronary artery disease; coronary microvascular dysfunction; coronary sinus reducer; microvascular angina.
Copyright © 2024 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Funding Support and Author Disclosures The study was supported by the Mayo Foundation and unrestricted grants from NeoVasc, Inc/Shockwave Medical Inc. and Phillips/Volcano. Protocol Number: (IRBe) 20-006386, IDE Number: G200153. The authors have reported that they have no relationships relevant to the contents of this paper to disclose.
Similar articles
-
Impact of severe COVID-19 infection on coronary microvascular dysfunction in ANOCA patients: A cross-sectional study.Atherosclerosis. 2025 Aug;407:120389. doi: 10.1016/j.atherosclerosis.2025.120389. Epub 2025 Jun 2. Atherosclerosis. 2025. PMID: 40483738
-
Chest pain patterns and coronary microvascular function in non-obstructive coronary artery disease.EuroIntervention. 2025 Sep 1;21(17):e995-e1004. doi: 10.4244/EIJ-D-25-00277. EuroIntervention. 2025. PMID: 40887985
-
Coronary Sinus Narrowing for Treating Refractory Angina: REDUCER-I Multicenter "Real-World" Observational Study Primary Endpoint Analysis.JACC Cardiovasc Interv. 2024 Dec 23;17(24):2908-2918. doi: 10.1016/j.jcin.2024.08.047. Epub 2024 Nov 6. JACC Cardiovasc Interv. 2024. PMID: 39520437
-
ANOCA updated: From pathophysiology to modern clinical practice.Cardiovasc Revasc Med. 2025 Feb;71:1-10. doi: 10.1016/j.carrev.2024.09.010. Epub 2024 Sep 21. Cardiovasc Revasc Med. 2025. PMID: 39341735 Review.
-
Invasive coronary physiology in patients with angina and non-obstructive coronary artery disease: a consensus document from the coronary microvascular dysfunction workstream of the British Heart Foundation/National Institute for Health Research Partnership.Heart. 2022 Dec 22;109(2):88-95. doi: 10.1136/heartjnl-2021-320718. Heart. 2022. PMID: 35318254 Free PMC article. Review.
Cited by
-
Segmental redistribution of myocardial blood flow after coronary sinus reducer implantation demonstrated by quantitative perfusion cardiovascular magnetic resonance.J Cardiovasc Magn Reson. 2025 Summer;27(1):101868. doi: 10.1016/j.jocmr.2025.101868. Epub 2025 Feb 26. J Cardiovasc Magn Reson. 2025. PMID: 40021090 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical